Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Temporal Interference Stimulation of Hypothalamus in Patients With Narcolepsy Type 1

NCT: NCT07727239 · NOT_YET_RECRUITING

NCT IDNCT07727239
StatusNOT_YET_RECRUITING
Start Date2026-07
Completion2027-12
SponsorXijing Hospital (OTHER)
First posted
Last updated

Brief Summary

Narcolepsy type 1 (NT1) is a chronic brain disorder caused by selective loss or dysfunction of orexin (hypocretin) neurons in the lateral hypothalamus, for which current pharmacological treatments offer limited efficacy. Temporal interference (TI) stimulation is a recently developed noninvasive neuromodulation technique that enables focal modulation of deep brain structures. In this randomized, double-blind study, we developed a theta-burst patterned TI protocol and evaluated its effects in patients with NT1.

Frequently Asked Questions

What is Temporal Interference Stimulation of Hypothalamus in Patients With Narcolepsy Type 1?

Temporal Interference Stimulation of Hypothalamus in Patients With Narcolepsy Type 1 is a clinical trial registered under NCT07727239. Current status: NOT_YET_RECRUITING.

What is the status of NCT07727239?

The current status of NCT07727239 (Temporal Interference Stimulation of Hypothalamus in Patients With Narcolepsy Type 1) is: NOT_YET_RECRUITING.

When did Temporal Interference Stimulation of Hypothalamus in Patients With Narcolepsy Type 1 start?

Temporal Interference Stimulation of Hypothalamus in Patients With Narcolepsy Type 1 started on 2026-07.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.